Potluri H, Atmakuri L. R, Nannapaneni U. R, Challari C, Shaik A. M, Potluri V. H. P. Antipyretic Potential of Tamarixetin from Ipomoea marginata (Desr.) Verdcourt and its Validation by Computational Studies. Biomed Pharmacol J 2026;19(2).
Manuscript received on :04-09-2025
Manuscript accepted on :11-03-2026
Published online on: 08-05-2026
Plagiarism Check: Yes
Reviewed by: Dr. Mu, Tianhong
Second Review by: Dr. Dunya Abdal-Malik
Final Approval by: Dr. Jihan Seid Hussein

How to Cite    |   Publication History
Views  Views: 
Visited 6 times, 7 visit(s) today
 

Haritha Potluri1*, Lakshmana Rao Atmakuri2, Usha Rani Nannapaneni3, Chakrapani Challari1, Abdul Mathin Shaik1and Venkata Hari Prasad Potluri4

1Department of Chemistry, Seshadri Rao Gudlavalleru Engineering College, Gudlavalleru, Andhra Pradesh, India.

2Department of Pharmaceutical Analysis, V. V. Institute of Pharmaceutical Sciences, Gudlavalleru, Andhra Pradesh, India.

3Department of FED, PVP Siddhartha Institute of Technology, Vijayawada, Andhra Pradesh, India.

4Department of Computer Science and Engineering, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur, Andhra Pradesh, India.

Corresponding Author E-mail: haritha.potluri@gmail.com

Abstract

Ipomoea marginata (Desr.) Verdcourt is traditionally used in hypertension, diabetes and fever therapies. This research aims to determine the potential antipyretic function of Ipomoea marginata methonolic crude extract (MEIM) and its fractions in order to facilitate its usage as folk medicine, and to detect the phytochemical components responsible for it by in vivo & in silico studies. MEIM & its fractions were subsequently examined through GC–MS analysis.  In vivo experiments were performed in Wistar albino mice by yeast-induced pyrexia test. In vivo antipyretic experiments demonstrated a substantial decrease of the rectal temperature of about 0.5°C in all doses for yeast-induced rat pyrexia. The molecular docking of certain significant compounds in MEIM to Cyclo-oxygenase-1, Cyclo-oxygenase-2 & Microsomal-Prostaglandin E Synthase-1 demonstrated noteworthy associations of these target proteins with the retained amino acid residue. Tamarixetin is the compound which attained best docking score. These findings suggest that Tamarixetin, isolated from Ipomoea marginata has a potential therapeutic efficacy for treating fever.

Keywords

ADMET; Antipyretic; In silico; Ipomoea marginata; Isolation

Copy the following to cite this article:

Potluri H, Atmakuri L. R, Nannapaneni U. R, Challari C, Shaik A. M, Potluri V. H. P. Antipyretic Potential of Tamarixetin from Ipomoea marginata (Desr.) Verdcourt and its Validation by Computational Studies. Biomed Pharmacol J 2026;19(2).

Copy the following to cite this URL:

Potluri H, Atmakuri L. R, Nannapaneni U. R, Challari C, Shaik A. M, Potluri V. H. P. Antipyretic Potential of Tamarixetin from Ipomoea marginata (Desr.) Verdcourt and its Validation by Computational Studies. Biomed Pharmacol J 2026;19(2). Available from: https://bit.ly/4nexhGW

Introduction

Over the years many diseases have been treated successfully using synthetic chemicals.1 Traditional herbal compounds often play an important role as medicine since ancient history, particularly in rural areas, where availability of modern medicine is limited.2,3 Phytochemicals (bioactive compounds) that serve as defensive mechanisms to fight different diseases have been shown to be found in plants.4,5 Many experiments have shown effectiveness in validating medicinal plants for multiple diseases.6-16 Ipomoea marginata (Convolvulaceae) is a perineal herb that grows to a height of 2-5 meter, the herb is widely spread in West Africa.17 Its plant juice is used as diuretic, antihypertensive, anti-diabetic, antidote and uterine tonic.18 The plant has been documented to produce various compounds that can be used to cure diseases with medicinal ingredients.19,20 The therapeutic properties of this plant was due to the availability of chemical compounds that aid healing processes. In light of these several effectiveness trials of I. marginata knowledge is scarce against a broad range of factors on specific disease of pyrexia.21

Pyrexia is a specific typical symptom defined outside the normal range by the rise in body temperature. The body offers an ideal habitat in which former natural protection mechanisms facilitate repair or render inviolable infectious agents. Increased hypothalamic prostaglandin E2 (PGE2) synthesis induces an uptick in body temperature through the release of tainted or impaired tissues.22 Almost, all existing antipyretic drugs hinder PGE2 production by the application of COX-2 inhibition. A few of these agents inhibit COX-2 through irreversible binding. Therefore, these synthetic agents may also exert toxic effects on the brain cortex, cardiac muscle, liver cells, and renal glomeruli. In contrast, natural COX-2 inhibitors are reported to be associated with comparatively fewer adverse outcomes.23

Therefore, in the present report, an attempt was done to examine antipyretic role of methanol extract of Ipomoea marginata (MEIM) & of different sub fractions petroleum ether (PEFIM), chloroform (CFIM)) with an effort to explain their native usage as febrifuge. To explore the findings of MEIM and phytoconstituents chosen to treat pyrexia, studies on anti-pyretic actions using an in vivo and in silico approach was conducted.

Materials and Methods

Plant Material Collection

New specimens of I. marginata were taken at Gudlavalleru, Andhra Pradesh. (16° 20′ 53.52” N and also 81° 3′ 5.5332” E). Identification of plant material was carried out, & corresponding voucher specimen was preserved in herbarium at V. V. Institute of Pharmaceutical Sciences. It was authenticated by S V University, Tirupati, Andhra Pradesh.

Preparation of Samples

The shade-dried plant matter was milled by means of milling apparatus into coarse powder. Approximately 1000 g of this powder underwent Soxhlet extraction using methanol to obtain the methanolic extract (MEIM). The resulting extract was subsequently partitioned by sequential extraction with petroleum ether (PEFIM), chloroform (CFIM), and diethyl ether (DEFIM). Each fraction was then filtered, concentrated through rotary evaporation under reduced pressure, and preserved under refrigerated conditions until analysis.

 GC-MS Analysis of MEIM

The gas chromatography analysis was performed on an Agilent 6890 Series instrument fitted with Agilent 5973 mass selective detector, operated through the Agilent Chemstation software and equipped with an HP-5MS capillary column. Ultra-high purity helium served as the carrier gas at constant flow rate of 1.0 milliL/min with constant speed of 37 cm/s. Injector temperature was held at 250℃. Oven program was initiated at 60℃ and stepped up to 280℃ in steps of 10℃ per minute with 4 min. each & Velectron multiplier voltage. The compounds were identified by direct comparing point. 2 μL injections are made with 20:1 split ratio, operated in 70 eV electron ionization rendered processing times with spectral information and separation patterns were cross-checked with the NIST library.24

Molecular Docking Study

AutoDock 4.0 was used in order to perform molecular docking studies & Discovery Studio Biovia 2020 to evaluate the interactions among ligands & their target proteins. Compounds selected for analysis included ferulic, vanillic, gentisic acid, proanthocyanidins, p-hydroxybenzoic acid, quercetin, and 3′,4′-dimethoxy derivatives (Figure 1). To this end, the three-dimensional crystal structures of COX-I (PDB ID: 3N8V), COX-II (PDB ID: 5KIR) and mPGES-1 (PDB ID: 3DWW) (Figure 2) were retrieved in Protein Data Bank.

Figure 1: The two-dimensional structures of in silico active ligands from Ipomoea marginata

Click here to view Figure

Figure 2: Three-dimensional structures of the molecular targets in their unbound (free) forms include: (A) Cyclooxygenase-1 (PDB ID: 3NRV), (B) Cyclooxygenase-2 (PDB ID: 5KIR), 

Click here to view Figure

Drug likeliness and ADMET Analysis

In this study, DruLiTo was engaged to evaluate drug-likeness of selected compounds.²⁵ Assessment of pharmacokinetic parameters was carried out to establish their behavior within body. ADMET properties were examined using admetSAR approach, while acute toxicity predictions were generated with the Test Estimation Software Tool (T.E.S.T).26-28

PASS Analysis

This software-based platform is designed to predict the possible physiological activities of compounds. For each substance, the outcomes are expressed as Pa & Pi (range 0.000 to 1.000). In present analysis, only activities where Pa exceeded Pi were observed.29,30

Isolation of 4’-Methoxy Quercetin

Column chromatography with the silica gel G as stationary phase was applied to the MEIM & eluted with gradient manner from 100% petroleum ether to 100% methanol. At a particular concentration from 40% ethyl acetate: 60% methanol got a fraction enriched with rich in flavonoids. Then that fraction was subjected to recolumn by sephadex LH-20 with an eluent 100% methanol, which results in production of light yellow powder. Purity of isolated compound melting point test done and structure elucidation using IR, NMR and mass spectroscopy.

Experimental animals

The experiments included Albino Wistar rats (120-150 g) obtained from Mahaveer’s animal resource firm, Hyderabad. The animals have been kept in sanitised polypropylene cages attain sterile paddy husk as bedding under normal environmental conditions. Seven days before analysis, animals were acclimatised. The animals were assigned to study and control groups and the food was withheld 12 hours prior to the study hours. All experimental protocols met with the IAEC and CPCSEA guidelines (Protocol No. P16/IAEC/VVIPS/PH/Rats-24).

Acute toxicity tests

Acute oral toxicity was assessed following the guidelines outlined in OECD Test No. 423.31 In the toxicity analysis, entirety of five animals inward single oral dose of 2000 millig/kilog bw of MEIM. Food was supplied for 3 or 4 hours after dosing. During the first 30 min after dosing, each animal was watched closely, regularly for the first 24 hours, and again for 3 days to record latent sensitivity. In order to measure the appropriate therapeutic dose, median fatal dose (LD50 > 2.0 g / kg) was identified according to Zaoui et al.32

Antipyretic testing

Anti-pyretic function of MEIM & its different sub-fractions has been measured by pyrexia with the administration of Brewer’s yeast suspension in Swiss mouse albinos of both sexes. The animals were classified into nine classes of five mice each. Using an automated thermometer, natural body temperature was registered and subsequently pyrexia was caused by administering a Brewer’s aqueous yeast suspension of 20% (10 ml/kg, sc). Every group fasted overnight, but permitted with free use of drinking water, and every mouse had a rectal temperature reported after 18 hours. Pyrexia induction was verified by temperature changes above 0.5ºC.33 Negative control (group I), standard drug (group II), tamarixetin (20 millig/kilog), and the rest of the groups (IV-IX) were fed MEIM, CFIM, PEFIM, at 200 millig/kilog level, or 400 millig/kilog level respectively. After administering control, normal & test samples, rectal temperature was reported one hour, two hours, three hours & four hours after the administration.

Statistical analysis

Data have been represented as the mean±SEM of five animals. For regression research, ANOVA was accompanied by a multiple comparison post hoc Dunnett test. The findings were found important at level p<0.05.

Results

GC-MS Analysis

Variety of compounds were identified in methanolic extract of Ipomoea marginata through GC–MS analysis. These compounds have been detected in the course of mass spectrometry linked to GC. The different biological active components of the whole herb of I. Marginata found by GC-MS were tabulated in Table 1. 

Table 1: Biological active compounds optained from Ipomoea marginata

Ligands Binding Affinity, ΔG (Kilocal/mol) Amino acids involved & Distance (A°)
Hydrogen Binding Hydrophobic Interactions Electrostatic Inter-actions
Inter-actions
Tamarixetin -8.1 ALA A:199 (3.67), TYR A:385 (3.57), ASN A:382 (3.22) PHE A:210 (6.46), HIS A:386 (4.68) MET A:391 (6.41)
4-hydroxy benzoic acid -5.9 LEU A:352 (5.63), GLY A:526 (4.84), ALA A:527 (4.27)
Cinnamic acid -6.3 TYR A: 355 (6.04) ALA A:527 (4.69), GLY A:526 (3.85), LEU A:352 (5.75), ILE A:523 (6.00)
Ferulic acid -6.3 TYR A:355 (5.94) ALA A:527 (4.56), ILE A:523 (6.47), GLY A:526 (4.78), LEU A:352 (5.31, 5.42), TYR A:348 (5.52), VAL A:349 (5.49)
Gentisic acid -6.3 SER A:530 (4.17) LEU A:352 (5.51), ILE A:523 (4.06), ALA A:527 (4.16), GLY A:526 (4.87)
Proanthocyanidins -8.4 PHE A:210 (6.02), ASN A:382 (3.99, 4.41), HIS A:386 (4.96), TRP A:387 (5.12) VAL A:447 (5.67), HIS A:388 (6.38)
Vanillic acid -6 HIS A:388 (4.08) HIS A:207 (5.49), MET A:391 (4.53), HIS A:388 (4.50, 4.95), HIS A:386 (3.49)
Paracetamol -6.1 HIS A:386 (3.82) ALA S:202 (5.22)

Molecular Docking Studies

All compounds identified through GC–MS were subjected to docking analysis against the target proteins COX-I (PDB ID: 3N8V), COX-II (PDB ID: 5KIR), and human microsomal prostaglandin E synthase-1 (PDB ID: 3DWW), and their performance was ranked based on docking scores. From this screening, seven molecules were shortlisted owing to their favorable binding affinities & interactions within active sites of 3N8V, 5KIR, and 3DWW (Figures 3–5). Among these, Tamarixetin demonstrated strong binding, with docking energies of –8.1, –9.5, & –7.8 kcal/mol against COX-I, COX-II, and mPGES-1, respectively (Tables 2–4).

Table 2: Interactions of COX-I (3N8V) amino acid residues with ligands at receptor sites

Ligands Binding Affinity, Amino acids involved & Distance (A°)
ΔG (Kcal/mol) Hydrogen Binding

Inter-actions

Hydrophobic

Inter-actions

Electrostatic Inter-actions
Tamarixetin -9.5 SER A: 353 (4.35), TYR A:385 (6.64), VAL A:344 (5.82), TYR A:348 (5.37), VAL A:349 (5.35, 4.88), LEU A:352 (4.30, 4.38), VAL A:523 (4.21, 4.86)
4-hydroxy benzoic acid -6.1 THR A:206 (3.28) ALA A:202 (4.19)
Cinnamic acid -6.7 TYR A:355 (5.10) VAL A:523 (5.30), LEU A:352 (5.78), ALA A:527 (3.93)
Ferulic acid -7.3 LEU A:352 (5.56), VAL A:523 (4.45), TRP A:387 (6.50), PHE A:518 (5.93), VAL A:349 (6.56, 4.85)
Gentisic acid -6.2 THR A:206 (3.45), TRP A:387 (6.17) ALA A:202 (4.18), HIS A:388 (6.73)
Proanthocyanidins -7.4 GLN A:289 (5.54), THR A:212 (4.69), GLN A:454 (5.09), VAL A:291 (5.75), HIS A:214 (6.31), HIS A:386 (5.85, 7.93), LEU A:294 (6.17)
Vanillic acid -6.2 TRP A:387 (5.53) HIS A:207 (6.72), HIS A:388 (5.25), TYR A:385 (6.43), HIS A:386 (3.82), ALA A:202 (6.09)
Paracetamol -6.1 ALA A:199 (3.68), THR A:206 (3.94) ALA A:202 (5.64), HIS A:386 (3.53)

Table 3: Interactions of COX-II (5IKR) amino acid residues with ligands at receptor sites

Ligands Binding Affinity, ΔG (Kcal/mol) Amino acids involved & Distance (A°)
Hydrogen Binding Hydrophobic Electrostatic Inter-actions
Inter-actions Inter-actions
Tamarixetin -7.8 ARG A:38 (4.27), ala a:43 (4.20), ARG A:60 (6.26), CYS A:59 (3.69), ARG A:67 (4.85), ILE A:33 (5.02), VAL A:37 (5.62), ARG A: 38 (6.55) LYS A:41 (4.61), ASP A:64 (4.41, 4.75), ARG A:67 (4.94)
4-hydroxy benzoic acid -4.9 ALA A:43 (3.89) ARG A:38 (4.67), LYS A:41 (4.12) ASP A:64 (5.09)
Cinnamic acid -5.4 ASP A:67 (3.97), ASP A:64 (2.66) ARG A:38 (6.18), LYS A:41 (4.95) ASP A:64 (5.75)
Ferulic acid -6.2 CYS A:68 (4.61), CYS A:59 (4.14), ARG A:60 (6.32) LYS A:41 (5.03), LYS A:42 (4.18), PHE A:44 (5.30), ARG A:38 (4.53), ASP A:64 (5.03)
Gentisic acid -5.4 LYS A:41 (5.73) ARG A:38 (6.42) ASP A:64 (4.46), LYS A:41 (4.77)
Proanthocyanidins -7.6 ARG A:67 (6.16) ALA A:43 (6.68), ARG A:38 (5.62), VAL A:37 (6.19), PRO A:63 (4.74) ASP A:64 (4.87), LYS A:41 (6.82), ARG A:67 (5.16)
Vanillic acid -5.5 ASP A:64 (4.34) ARG A:38 (5.80), LYS A:41 (4.46), PHE A:44 (4.99), ALA A:43 (3.96), ARG A:60 (5.00) ASP A:64 (5.23)
Paracetamol -4.7 ARG A:110 (5.65), ARG A:126 (6.25) ALA A:133 (4.52)

Table 4: Interactions of human microsomal prostaglandin E synthase 1 (PDB ID: 3DWW) amino acid residues with ligands at receptor sites

S. No Retention Time Compound name Canonical Smiles Area (%) Mol. formula Mol. weight
1 6.252 4-Hydroxybenzoic acid OC(c(cc1)ccc1O)=O 8.68 C7H6O3 138.12
2 6.647 Gentisic acid OC(c (cc(cc1)O)c1O)=O 5.22 C7H6O4 154.12
3 8.292 Vanillic acid COc(c c(cc1)C(O)=O)c1O 10.98 C8H8O4 168.15
4 8.917 Ferulic acid COc(cc(/C=C\C(O)=O)cc1)c1O 5.53 C10H10O4 194.18
5 11.334 Tamarixetin COc(ccc(C(Oc(cc(cc1O) O)c1C1=O)=C1O)c1)c1O 48.23 C16H12O7 316.26
6 13.324 Proanthocyanidins O[C @ H] ([C@ H] 1O ) [C@](c(cc2)cc(O)c2O)(O[C@@H](C2)[C@@H](c(cc3)cc(O)c3O)Oc3c2c(O)cc(O)c3)Oc2c1c(O)cc(O)c2 10.14 C30H26O13 594.5
7 14.985 Cinnamic acid C1= CC= C(C= C1) C= CC (=O)O 6.28 C9H8O2 148.16
 Figure 3: 2D Interactions of Ligands with COX-I (PDB ID: 3N8V). A) Tamarixetin B) 4-hydroxy benzoic acid C) Cinnamic acid D) Ferulic acid E) Gentisic acid F) Proanthocyanidins G) Vanillic acid H) Paracetamol

Click here to view Figure

Figure 4: 2D Interactions of Ligands with COX-II (PDB ID: 5KIR). A) Tamarixetin B) 4-hydroxy benzoic acid C) Cinnamic acid D) Ferulic acid E) Gentisic acid F) Proanthocyanidins G) Vanillic acid H) Paracetamol

Click here to view Figure

Figure 5: 2D Interactions of Ligands with human microsomal prostaglandin E synthase 1 (3DWW). A) Tamarixetin B) 4-hydroxy benzoic acid C) Cinnamic acid D) Ferulic acid E) Gentisic acid F) Proanthocyanidins G) Vanillic acid H) Paracetamol

Click here to view Figure

Drug likeliness

Lipinski’s rule of 5 is commonly applied to predict oral bioavailability of drug-like molecules in humans.³⁴ The physicochemical parameters of ten compounds selected from the docking study were evaluated using the DataWarrior software, & results are summarized in Table 5. With exception of proanthocyanidins, which deviated in molecular weight and hydrogen bond acceptor count, all molecules complied with the rule. The distribution plots indicated that most compounds were located within ‘Lipinski compliant’ region (MW < 500, logP < 5, HBA < 10, HBD < 5).

Table 5: Physicochemical characteristics of active substances & compliance with principles of drug-likeness

Compound MW logp Alogp HBA HBD TPSA AMR nRB
Ferulic acid 184 0.78 0.267 4 0 26.3 55.45 3
Vanillic acid 160 0.51 -0.09 4 0 26.3 45.2 2
Gentisic acid 148 0.62 -0.16 4 0 17.07 40.17 1
Proanthocyanidins 567.9 1.5 -2.07 13 0 27.69 161.2 4
4-Hydroxybenzoic acid 132 0.27 0.405 3 0 17.07 38.56 1
Tamarixetin 304 1.73 -1.18 7 0 35.53 88.48 2

Pass Analysis

Biological activity spectra of the ligands were predicted using PASS online, and the outcomes are summarized in Table 6. Compounds with Pa values greater than 0.7 were considered highly likely to demonstrate the predicted activity in experimental conditions, whereas those with Pa values below 0.5 were regarded as unlikely to exhibit such activity.35

Table 6: PASS analysis of different compounds from Ipomoea marginata

Compound Antiviral (Picornavirus) Antiviral (Influenza) Antiviral (Adenovirus) Antiviral (Rhinovirus) Antiviral (CMV) Antiviral (Herpes)
Pa Pi Pa Pi Pa Pi Pa Pi Pa Pi Pa Pi
Ferulic acid 0.62 0.02 0.58 0.01 0.54 0 0.54 0 0.37 0.01 0.38 0.04
Vanillic acid 0.5 0.05 0.56 0.02 0.45 0.01 0.46 0.04 0.33 0.02 0.36 0.06
Gentisic acid 0.63 0.01 0.53 0.04 0.47 0.01 0.41 0.08 0.36 0.01 0.35 0.06
Proanthocyanidins 0.44 0.04 0.55 0.01 0.44 0.02
4-Hydroxy benzoic acid 0.62 0.02 0.58 0.01 0.54 0 0.49 0.03 0.37 0.01 0.38 0.04
Tamarixetin 0.37 0.06 0.47 0.01

ADMET Analysis

ADMET characteristics of ligands were assessed with the aid of the admetSAR platform, & results are provided in Table 7. All compounds demonstrated excellent HIA and strong BBB permeability. High HIA values indicate the potential for effective oral absorption. In addition, all ligands tested negative in the AMES assay, suggesting a non-mutagenic profile. Toxicity evaluation revealed that compounds with lower LD₅₀ values exhibited higher toxicity compared to those with higher LD₅₀ values.³⁶

Table 7: ADMET Properties of different compounds from Ipomoea marginata

Compound HIA BBB AMES Toxicity Carcinogenicity LD50 in rat (mol/kg)
Ferulic acid 0.9614 0.5305 Non-toxic Non-carcinogenic 1.4314
Vanillic acid 0.9231 0.5146 Non-toxic Non-carcinogenic 1.8710
Gentisic acid 0.9223 0.6660 Non-toxic Non-carcinogenic 2.1788
Proanthocyanidins 0.6772 0.5112 Non-toxic Non-carcinogenic 2.2049
4-Hydroxybenzoic acid 0.9872 0.5320 Non-toxic Non-carcinogenic 1.3983
Tamarixetin 0.9783 0.6382 Non-toxic Non-carcinogenic 2.7192
Paracetamol 0.9544 0.9921 Non-toxic Non-carcinogenic 1.8596

Acute toxicity studies

No mortality was observed with the extracts and fractions of I. marginata at doses up to 2000 mg/kg. Therefore, 1/10th & 1/5th of this dose (200 and 400 mg/kg) were selected for subsequent experiments.

Characterization of Tamarixetin

The compound isolated from methanolic extract of Ipomoea marginata was characterized as Tamarixetin. It exhibited a melting point of 195–197 ºC. UV (MeOH) absorption maxima were recorded at 257 and 357 nm. The ^1H NMR spectrum (400 MHz, CDCl₃) displayed signals at δ 7.77 (1H, dd, J = 9.0, 1.8 Hz), 7.37 (1H, d, J = 9.0 Hz), 7.33 (1H, d, J = 1.9 Hz), 7.26 (1H, s), 6.54 (1H, d, J = 2.0 Hz), 6.43 (1H, d, J = 1.8 Hz), and 4.05 (2H, s). The ^13C NMR spectrum (400 MHz, CDCl₃) showed signals at δ 177.67, 165.13, 160.84, 157.69, 150.26, 147.33, 146.63, 136.33, 123.05, 120.17, 114.62, 112.77, 103.23, 99.58, 94.40, and 56.21 (Figure 6). 

Figure 6: Structure of the isolated compound from Ipomoea marginate (Tamarixetin).

Click here to view Figure

Antipyretic test

Statistical research indicates the methanol extracts as well as subfractions of I. marginata demonstrated strong antipyretic impact. MEIM and their subfractions showed significant effects at intervals of 2, 3 and 4 hours. Tamarixetin on the other side, with the 20 mg/kg dosage, had highly significant effects at all stages. The influence on the rectal temperature of the extract and fractions in mice are as seen in Table 8 and Figure 7.

Table 8: Antipyretic activity of extract & fractions of Ipomoea marginata by Brewer’s yeast-induced pyrexia method

Groups Initial rectal Temperature before yeast injection (°C) Rectal temperature at yeast injection & after the administration of sample (°C)
0 hr 1st hour 2nd hour 3rd hour 4th hour
Control 37.47±0.15 38.02±0.67 38.12±0.21 38.04±0.09 38±0.10 38.04±0.12
Paracetamol 37.07±0.32 38.18±0.17 37.87±0.37$ 37.43±0.13$ 37.24±0.09$ 36.94±0.14$
Tamarixetin (20 mg/kg) 37.23±0.56 38.11±0.22 37.95±0.36$ 37.73±0.11$ 37.54±0.12$ 37.26±0.41$
MEIP (200 mg/kg) 37.42±0.11 38.06±0.18 38.05±0.15* 37.8±0.12* 37.72±0.67* 37.61±0.18*
MEIP (400 mg/kg) 37.79±0.32 37.78±0.63 37.51±0.62 37.28±0.06$ 37.15±0.17$ 37.1±0.20$
PEFIP (200 mg/kg) 37.56±0.18 38.28±0.42 38.23±0.41 37.91±0.23* 37.78±0.12* 37.75±0.89*
PEFIP (400 mg/kg) 37.18±0.26 38.26±0.52 37.64±0.11 37.37±0.20% 37.26±0.67% 37.25±0.19%
CFIM (200 mg/kg) 37.21±0.52 37.91±0.47 37.88±0.26% 37.47±0.09% 37.37±0.12* 37.21±0.67*
CFIM (400 mg/kg) 37.1±0.25 38.05±0.13 37.6±0.15$ 37.22±0.05$ 37.08±0.20$ 36.97±0.33$

Values are expressed as mean±SEM or percentage (n = 5). The data were analyzed by one-way ANOVA followed by Dunnett’s test. *p < 0.05, %, p < .01, and $, p < .001 compared with control. 

Figure 7: Comparison between antipyretic effects of methanol extract of Ipomoea marginata with its fractions at dose level of 200 & 400 mgkg-1 body weight on Brewer’s yeast-induced pyrexia in rats

Click here to view Figure

Discussion

In this study, antipyretic effects of MEIM; their subfractions and Tamarixetin have been seen. Subcutaneous Brewer yeast injection improves the development of prostaglandins that induce pyrexia. Pyrexia brewer is a yeast-induced technique known as a convenient test for antipyretic effects of plant and synthetic products.37,38 Antipyretic activity may be done by inhibiting prostaglandin production, which can be accomplished by blocking the cyclooxygenase (COX) enzyme function. Many mediators, like TNF-α, IL-1, IL-6, engage in a rise in temperatures and may be responsible for antipyretic reactions by decreasing their involvement.39 Subcutaneous administration of S. cerevisiae, the components of cell walls serve as exogenous pyrogens that trigger immune cells in rodents including lymphocytes and macrophages. The release of endogenous pyrogens is cytokines that get access to hypothalamus via circulation and result in changes in body temperature of the handled mice.40 MEIM and its subfractions also lowered temperature of rectal of handled mice significantly. Decrease in temp. can be induced by existence of Tamarixetin in I. marginata, a pharmacologically active portion that interact with prostaglandin synthesis. However, during the biosynthesis of prostaglandins, numerous biological events occur and more study is required to establish exactly the degree to which Tamarixetin exercises its antipyretic effects.

This analysis was mainly based on the discovery of useful natural products from Ipomoea marginata herbal plant with sufficient pharmacological performance and minimal toxicity against pyresis. The seven phytoconstituents from I. marginata picked from this result is selected for further analysis explicitly.

The computer-aided drug design (CADD) software PASS has been used to speed up effective natural product study in order to forecast biological behaviour. The prediction method was to use 20,000 primary substances.41 Prediction findings were displayed as Pa & Pi ratio. This experiment demonstrated the highest Pa benefit for all antipyretic actions in vanillic acid, gentisic acid, and tamarixetin. Tamarixetin had a higher antipyretic activity rate of 0.735 Pa. The docking studies indicate that tamarixetin is the powerful compound of these seven compounds, although more in vivo studies had also studied its mechanism. The findings are also compatible with the literature as tamarixetin had antipyretic properties in a previous study.42

With respect to the COX-I enzyme, the least binding capacity of proanthocyanidins -8.4 Kcal/mol and found to make 3 hydrogen bonds, i.e. PHE A:210, ASN A:382, HIS A:386, TRP A:387; the development of hydrophobic associations requires two amino acids VAL A:447, HIS A:388. Tamarixetin established hydrogen bonding with ALA A:199, TYR A:385, ASN A:382 hydrophobic interactions with PHE A:210, HIS A:386 and electrostatic interactions with MET A:391.

In the enzyme pocket of COX-II, tamarixetin was better observed to be stabilised by the presence of a hydrogen bond  with SER A: 353 and hydrophobic interactions with TYR A:385, VAL A:344, TYR A:348, VAL A:349, LEU A:352, VAL A:523 with a docking score -9.5 Kcal/mol. Proanthocyanidins also attaches to the COX-II enzyme pocket by establishing a sequence of H-bonds with GLN A:289, THR A:212, GLN A:454, residues and hydrophobic interactions with  VAL A:291, HIS A:214, HIS A:386, LEU A:294 (docking score: -7.4 Kcal/mol).

In the enzyme pocket of microsomal prostaglandin E synthase 1, tamarixetin was better observed to be stabilised by the presence of five hydrogen bonds with ARG A:38, ALAA:43, ARG A:60, CYS A:59, ARG A:67 and hydrophobic interactions with ILE A:33, VAL A:37, ARG A: 38 with docking score of -7.8 Kcal/mol; followed by Proanthocyanidins with docking source of -7.6 Kcal/mol.

In all the in silico studies, two compounds had the least dock score against 3N8V, 5KIR, 3DWW i.e., tamarixetin and proanthocyanidins. Among these two compounds, tamarixetin had good HIA and BBB and as per PASS analysis also, Tamarixetin had good predictive antipyretic activity.43

Lipinski’s rule of 5 is a widely accepted guideline for evaluating drug-likeness, as it highlights key molecular features that influence pharmacokinetic processes such as ADME.44 Although the three top-ranked compounds did not fully comply with Lipinski’s criteria—mainly due to deviations in hydrogen bond donors and acceptors associated with their natural origin—ADME profiling of seven selected compounds confirmed that all passed the screening parameters (Table 7). This initial in-silico evaluation provides a rapid approach for identifying potential candidates for antipyretic therapy.

Conclusion

It can be inferred beyond any uncertainty that tamarixetin has beneficial structural features that effectively associate and inhibit COX-I, COX-II and mPGES-1, based on the strongly supportive binding energy values obtained in our research into In Silico and in vivo. This suggests that tamarixetin is a safe antipyretic and a promising future lead compound for safe antipyretic medicines.

Acknowledgement

The authors were thankful to the management of Seshadri Rao Gudlavalleru Engineering College, Gudlavalleru for funding the research and the generous support of V. V. Institute of Pharmaceutical Sciences, Gudlavalleru to conduct this research project.

Funding Sources

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

The author(s) declare no conflicts of interest in this work.

Data Availability Statement

This statement does not apply to this article.

Ethics Statement

Ethical approval was obtained to carryout research on animal subjects with ethical approval number P16/IAEC/VVIPS/PH/Rats-24.

Informed Consent Statement

This study did not involve human participants, and therefore, informed consent was not required.

Clinical Trial Registration

This research does not involve any clinical trials.

Permission to reproduce material from other sources

Not applicable

Author Contributions

  • Haritha Potluri: Conceptualization, Methodology, Writing – Original Draft;
  • Lakshmana Rao Atmakuri: Data Collection, Analysis;
  • Usha Rani Nannapaneni: Project Administration, Writing – Review & Editing;
  • Chakrapani Challari: Funding Acquisition, Resources;
  • Abdul Mathin Shaik: Supervision, Data Interpretation;
  • Venkata Hari Prasad Potluri: Visualization, Final Draft Approval. 

References

  1. Vasanthi B, Komathi J, Arun K. Therapeutic effect of vitamin E in patients with primary osteoarthritis. Int J Recent Adv Pharm Res. 2012;2:46-50.
  2. Kiringe JW. A survey of traditional health remedies used by the Maasai of Southern Kaijiado District, Kenya. Ethnobot Res Appl. 2006;4: 61-74.
    CrossRef
  3. Kalaivani R, Devi VJ, Umarani R, et al. Antimicrobial activity of some important medicinal plant oils against human pathogens. J Biol Act Prod Nat. 2012;2(1):30-37.
    CrossRef
  4. Soetan KO, Aiyelaagbe OO. The need for bioactivity-safety evaluation and conservation of medicinal plants – a review. J Med Plants Res. 2009;3(5):324-328.
  5. Recio MC, Andujar I, Rios JL. Anti-inflammatory agents from plants: progress and potential. Curr Med Chem. 2012;19(14):2088-2103.
    CrossRef
  6. Hosseinzadeh H, Younesi HM. Antinociceptive and anti-inflammatory effects of Crocus sativus L. stigma and petal extracts in mice. BMC Pharmacol. 2002;2(1):7.
    CrossRef
  7. Shilpi JA, Islam ME, Billah M, et al. Antinociceptive, anti-inflammatory, and antipyretic activity of mangrove plants: a mini review. Adv Pharmacol Sci. 2012;576086.
    CrossRef
  8. Elisabetsky E, Amador TA, Albuquerque RR, et al. Analgesic activity of Psychotria colorata (Willd. ex R. & S.) Muell. Arg. alkaloids. J Ethnopharmacol. 1995;48(2):77-83.
    CrossRef
  9. Yodsaoue O, Karalai C, Ponglimanont C, et al. Potential anti-inflammatory diterpenoids from the roots of Caesalpinia mimosoides Lamk. Phytochem. 2010;71(14-15):1756-1764.
    CrossRef
  10. Haritha P, Prasanth DSNBK, Lakshmana Rao A. In vivo antinociceptive effect of methanolic extract of Ipomoea marginata Desr. in rodents as well as in silico molecular docking of some phytoconstituents from the plant. Indian J Pharm Sci. 2021;83(4):732-741.
    CrossRef
  11. Prasanth DSNBK, Manikanta M, Chandramohan V, Bhavya G, Lakshmana Rao A, Panda SP, Rao GSNK, Chakravarthi G, Teja N, Suguna Rani P, Ashu G, Purnadurganjali C, Akhil P, Vedita Bhavani G, Jaswitha T. In-silico strategies of some selected phytoconstituents from Melissa officinalisas SARS CoV-2 main protease and spike protein (COVID-19) inhibitors. Mol Simul. 2021:1–14.
    CrossRef
  12. Prasanth DSNBK, Aminabee Sk, Lakshmana Rao A, Siva Prasad Panda, Teja N, Sandhya T, Bhargavi K, Monika Ch, Pujitha B, Lalitha A. Anthelmintic Activity of Mansoa alliacea against Pheretima posthuma: In vitro and In silico Thai J Pharm Sci. 2020;44(3):186-196.
    CrossRef
  13. S.N.B.K. Prasanth, Siva Prasad Panda, A. Lakshmana Rao, G. Chakravarti, N. Teja, V. Bhavya Naga vani and T. Sandhya. In-silico Strategies of Some Selected Phytoconstituents from Zingiber officinale as SARS CoV-2 Main Protease (COVID-19) Inhibitos. Indian J Pharm Educ Res. 2020;54(3)Suppl:S552-S559.
    CrossRef
  14. Srikanth Kumar K, Lakshmana Rao A, Basaveswara Rao MV. Design, synthesis, biological evaluation and molecular docking studies of novel 3-substituted-5-[(indol-3-yl)methylene]-thiazolidine-2,4-dione derivatives. Heliyon. 2018;4(9):e00807.
    CrossRef
  15. Srikanth Kumar K, Lakshmana Rao A, Rama Sekhara Reddy D. Design, synthesis, hypoglycemic activity and molecular docking studies of 3-substituted-5-[(furan-2-yl)-methylene]-thiazolidine-2,4-dione derivatives. Indian J Pharm Educ Res. 2021;55(1):266-275.
    CrossRef
  16. Srikanth Kumar K, Lakshmana Rao A, Basaveswara Rao MV, et al. Synthesis and hypoglycemic and anti-inflammatory activity screening of novel substituted 5-[morpholino(phenyl)methyl]-thiazolidine-2,4-diones and their molecular docking studies. Turk J Pharm Sci. 2019;16(4):380-391.
    CrossRef
  17. Aminabee Sk, Lakshmana Rao A. Computational identification of selected bioactive compounds from Cedrus Deodara as inhibitors against SARS-CoV-2 main protease: a pharmacoinformatics study. Indian Drugs. 2024;61(2):78-91.
    CrossRef
  18. Quattrocchi U. CRC world dictionary of medicinal and poisonous plants: common names, scientific names, eponyms, synonyms, and etymology (5 Volume Set): CRC press. 2012.
  19. Daniel M. Medicinal plants: chemistry and properties: Science publishers; 2006.
  20. Banso A, Adeyemo SO. Evaluation of antibacterial properties of tannins isolated from Dichrostachys cinerea. Afr J Biotechnol. 2007;6(15):1785-1787.
    CrossRef
  21. Meena PD, Kaushik P, Shukla S, et al. Anticancer and antimutagenic properties of Acacia nilotica (Linn.) on 7,12-dimethylbenz(a)anthracene-induced skin papillomagenesis in Swiss albino mice. Asian Pac J Cancer Prev. 2006;7(4):627-632.
  22. Khan A, Rahman M, Islam S. Antipyretic activity of Peperomia pellucida leaves in rabbit. Turkish Journal of Biology. 2008;32(1):37-41.
  23. Emran B, Talha, Tajbiha-E-Mowla, et al.  Sedative, anxiolytic, antinociceptive, anti-inflammatory and antipyretic effects of a chloroform extract from the leaves of Urena Sinuata in rodents. J Appl Life Sci Int. 2018;16(3):1-19.
    CrossRef
  24. Luo C, He M-l, Bohlin L. Is COX-2 a perpetrator or a protector? selective COX-2 inhibitors remain controversial. Acta Pharmacol Sin. 2005;26(8):926-933.
    CrossRef
  25. Kanthal LK, Dey A, Satyavathi K, et al.  GC-MS analysis of bio-active compounds in methanolic extract of Lactuca runcinata DC. Pharmacog Res. 2014;6(1):58-61.
    CrossRef
  26. Sander T, Freyss J, von Korff M, et al. C. OSIRIS, an entirely in-house developed drug discovery informatics system. J Chem Inf Model. 2009;49(2):232-246.
    CrossRef
  27. Cheng F, Li W, Zhou Y, et al. admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model. 2012;52(11):3099-4105.
    CrossRef
  28. Yang H, Lou C, Sun L, et al. admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties. Bioinform. 2019;35(6):1067-1069.
    CrossRef
  29. Barron MG, Jackson CR, Awkerman JA. Evaluation of in silico development of aquatic toxicity species sensitivity distributions. Aquat Toxicol. 2012;116-117:1-7.
    CrossRef
  30. Goel RK, Singh D, Lagunin A, et al.  PASS-assisted exploration of new therapeutic potential of natural products. Med Chem Res. 2011;20(9):1509-1514.
    CrossRef
  31. Mittal M, Goel RK, Bhargava G, et al. PASS-assisted exploration of antidepressant activity of 1, 3, 4-trisubstituted-β-lactam derivatives. Bioorg Med Chem Lett. 2008;18(20):5347-5349.
    CrossRef
  32. Jonsson M, Jestoi M, Nathanail AV, et al.  Application of OECD Guideline 423 in assessing the acute oral toxicity of moniliformin. Food Chem Toxicol. 2013;53:27-32.
    CrossRef
  33. Zaoui A, Cherrah Y, Mahassini N, et al. Acute and chronic toxicity of Nigella sativa fixed oil. Phytomed. 2002;9(1):69-74.
    CrossRef
  34. Prasanth DSNBK, Murahari M, Chandramohan V, Panda SP, Atmakuri LR, Guntupalli C. In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2. J Biomol Struct Dyn. 2021;39(13):4618-4632.
    CrossRef
  35. Kang JY, Khan MN, Park NH, et al. Antipyretic, analgesic, and anti-inflammatory activities of the seaweed Sargassum fulvellum and Sargassum thunbergii in mice. J Ethnopharmacol. 2008;116(1):187-190.
    CrossRef
  36. Ibrahim MAA, Abdeljawaad KAA, Abdelrahman AHM, et al.  Natural-like products as potential SARS-CoV-2 M(pro) inhibitors: in-silico drug discovery. J Biomol Struct Dyn. 2020:1-13.
    CrossRef
  37. Lagunin A, Stepanchikova A, Filimonov D, et al. PASS: prediction of activity spectra for biologically active substances. Bioinform. 2000;16(8):747-748.
    CrossRef
  38. Nisha CM, Kumar A, Nair P, et al. Molecular docking and in silico ADMET study reveals acylguanidine 7a as a potential inhibitor of β-secretase. Adv Bioinformatics. 2016;2016:9258578.
    CrossRef
  39. Devi BP, Boominathan R, Mandal SC. Evaluation of antipyretic potential of Cleome viscosa Linn. (Capparidaceae) extract in rats. J Ethnopharmacol. 2003;87(1):11-13.
    CrossRef
  40. Khan I, Nisar M, Ebad F, et al.  Anti-inflammatory activities of Sieboldogenin from Smilax china Linn.: experimental and computational studies. J Ethnopharmacol. 2009;121(1):175-177.
    CrossRef
  41. Rawlins M, Postgrad R, editors. Mechanism of salicylate-induced antipyresis. Pharmacology Thermoregulatory Proceeding Satellite Symposium; 1973.
  42. Ettinger SJ, Feldman EC, Cote E. Textbook of Veterinary Internal Medicine-eBook: Elsevier health sciences; 2017.
  43. Shao W, Brown M. Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. 2004;6(1):39-52.
    CrossRef
  44. Wang HJ, Pao LH, Hsiong CH, et al. Dietary flavonoids modulate cyp2c to improve drug oral bioavailability and their qualitative/quantitative structure–activity relationship. AAPS J. 2014;16(2):258-268.
    CrossRef

Abbreviations

ADMETAbsorption, Distribution, Metabolism, Excretion and Toxicity GC-MS – Gas Chromatography-Mass Spectrometry,  CADD – Computer Aided Design Drawing, PASS – Power Analysis and Sample Size,

Share Button
Visited 6 times, 7 visit(s) today

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.